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OBJECTIVES To assess the clinical significance of inducible ventricular tachyarrhythmias among patients
with unexplained syncope.
BACKGROUND Induction of sustained ventricular arrhythmias at electrophysiology study in patients with
unexplained syncope and structural heart disease is usually assigned diagnostic significance.
However, the true frequency of subsequent spontaneous ventricular tachyarrhythmias in the
absence of antiarrhythmic medications is unknown.
METHODS In a retrospective case-control study, the incidence of implantable cardiac defibrillator (ICD)
therapies for sustained ventricular arrhythmias among patients with unexplained syncope or
near syncope (syncope group, n 5 22) was compared with that of a control group of patients
(n 5 32) with clinically documented sustained ventricular tachycardia (VT). Sustained
ventricular arrhythmias were inducible in both groups and neither group received antiar-
rhythmic medications. All ICDs had stored electrograms or RR intervals. Clinical variables
were similar between groups except that congestive cardiac failure was more common in the
syncope group.
RESULTS Kaplan-Meier analysis of the time to first appropriate ICD therapy for syncope and control
groups produced overlapping curves (p 5 0.9), with 57 6 11% and 50 6 9%, respectively,
receiving ICD therapy by one year. In both groups, the induced arrhythmia was significantly
faster than spontaneous arrhythmias, but the cycle lengths of induced and spontaneous
arrhythmias were positively correlated (R 5 0.6, p , 0.0001). During follow-up, three cardiac
transplantations and seven deaths occurred in the syncope group, and two transplantations
and five deaths occurred in the control group (36-month survival without transplant 52 6
11% and 83 6 7%, respectively, p 5 0.03).
CONCLUSIONS In patients with unexplained syncope, structural heart disease and inducible sustained
ventricular arrhythmias, spontaneous sustained ventricular arrhythmias occur commonly and
at a similar rate to patients with documented sustained VT. Thus, electrophysiologic testing
in unexplained syncope can identify those at risk of potentially life-threatening tachyarrhyth-
mias, and aggressive treatment of these patients is warranted. (J Am Coll Cardiol 1999;34:
2023–30) © 1999 by the American College of Cardiology
The development of syncope in patients with structural
heart disease is associated with an increased risk of sudden
death (1). Understandably, many clinical investigators be-
lieve that in a significant proportion of these patients,
syncope represents the first presentation of a potentially
life-threatening ventricular tachyarrhythmia that fortu-
itously and spontaneously resolved. Programmed ventricular
stimulation is a useful technique for reliably reproducing
previously documented sustained ventricular tachycardia in
patients with coronary artery disease and to a lesser extent in
those with cardiomyopathy (2,3). Although electrophysi-
ologic testing has proved less sensitive in detecting brady-
arrhythmias, because of its potential value in detecting
tachyarrhythmias, it has become established in the investi-
gation of unexplained syncope in patients with heart disease
(4–7). Indeed, induction of clinically significant ventricular
tachyarrhythmias in patients with unexplained syncope and
structural heart disease is now a class 1 indication for
implantation of an implantable cardiac defibrillator (ICD)
(8).
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Electrophysiologic testing in unselected patients with
unexplained syncope predominantly yields negative results
and among such low risk patients, the potential for false
positive results is greatest (8–12). Including induction of
ventricular flutter or fibrillation with three extrastimuli may
also increase false positive results (13–15), although induc-
tion of such arrhythmias by two or less extrastimuli may be
a more clinically relevant end point (16). Thus, reported
results of electrophysiologic testing in syncope patients vary
widely according to patient selection, the pacing protocol
used and the definition used for clinically relevant inducible
tachyarrhythmias. Furthermore, even when electrophysi-
ologic study (EPS) guided drug therapy is used, patients
with inducible ventricular arrhythmias have a worse prog-
nosis than their noninducible control subjects (4,12,17–21).
Thus, using conventional techniques and therapies, a valid
assessment of the true value of electrophysiologic testing in
patients with unexplained syncope has been fraught with
difficulties.
The development of ICDs with facility for recording
electrograms or RR intervals when combined with appro-
priate patient selection and a refined programmed stimula-
tion protocol allows, for the first time, a valid assessment of
the significance of sustained ventricular tachycardia (VT)
initiated at electrophysiologic testing in patients with unex-
plained syncope. In this study, we examined the incidence
during follow up of appropriate ICD therapies (defibrilla-
tions) among patients with syncope, structural heart disease
and inducible sustained ventricular tachyarrhythmias. As a
control group, we used patients with documented sustained
VT and inducible sustained VT who were treated with ICD
implantation.
METHODS
Study patients. In patients who receive an ICD, our
standard policy is to avoid routine administration of antiar-
rhythmic drug therapy unless needed to control frequent
arrhythmias. This policy allowed us to perform a retrospec-
tive case-control study comparing the incidence of appro-
priate ICD therapies, in the absence of antiarrhythmic drug
therapy, between patients with unexplained syncope (syn-
cope group) with those who had documented spontaneous
sustained VT (control group).
Cases and controls were identified from our register of
ICD implants. All patients who had a device with capability
of storing electrograms or RR intervals implanted before
January 1, 1996 were evaluated for inclusion in the study. Of
these 175 patients, 30 potential cases with a history of
unexplained syncope and 93 potential control subjects with
a history of documented sustained VT were identified. Six
syncope and 47 control patients were excluded because they
were receiving antiarrhythmic drug therapy at the time of
their initial clinical event, diagnostic EPS or during
follow-up prior to their first appropriate ICD therapy. A
further two cases and 14 control subjects were excluded
because of noninducibility at initial EPS. Thus, the study
groups consisted of 22 syncope patients and 32 control
subjects.
Our policy for the use of EPS in the clinical investigation
of unexplained syncope has restricted the use of EPS to
those patients with structural heart disease who had first
been clinically assessed by an electrophysiologist (E.N.P.,
J.J.E., R.I.F.). In addition, all patients underwent at least
48 h of telemetry monitoring prior to EPS. Other cardiac
workup included cardiac catheterization in 91% of the
syncope group and 100% of control subjects, nuclear stress
tests in those who did not undergo cardiac catheterization
and in all patients whose catheterization predated the EPS
by . six months. LV ejection fraction was calculated from
radionuclide angiography (41% of syncope patients and 38%
of control subjects), echocardiography or from cardiac
catheterization data.
Electrophysiology study. Studies were performed in the
postabsorptive state, after withdrawal of all antiarrhythmic
drug therapy for $5 half-lives (3). Patients were sedated
with 1 to 4 mg of intravenous midazolam. Two to three
multipolar electrode catheters were percutaneously inserted
under local anesthesia through the femoral vein and ad-
vanced under fluoroscopic guidance to the high right
atrium, His bundle area and right ventricle. Spontaneous
intervals were obtained as well as corrected sinus node
recovery times (syncope only), atrioventricular node and
His-Purkinje conduction and refractoriness, and evaluation
of inducible supraventricular tachycardia and VT (10). The
programmed ventricular stimulation protocol utilized up to
three extrastimuli at two paced cycle lengths starting at the
RV apex, then testing the RV outflow tract if no sustained
ventricular arrhythmias were induced. Attempts to repro-
duce the sustained ventricular arrhythmia were always made
unless defibrillation had already been required. The Multi-
center Unsustained Tachycardia Trial (MUSTT) defi-
nitions of ventricular tachyarrhythmias, and the clinical
relevance of their induction, were adopted (16). In brief,
induction of sustained ($30 s or requiring termination
because of loss of consciousness) monomorphic VT by #3
ventricular extrastimuli and induction of sustained ventric-
ular flutter or fibrillation by #2 ventricular extrastimuli were
considered clinically relevant tachyarrhythmias. Ventricular
flutter was defined as a rapid monomorphic VT with a cycle
Abbreviations and Acronyms
CL 5 cycle length of tachyarrhythmia
EPS 5 electrophysiology study
HV 5 His to ventricular conduction time
ICD 5 implantable cardiac defibrillator
RR 5 interval between succeeding QRS complexes
VT 5 ventricular tachycardia
2024 Andrews et al. JACC Vol. 34, No. 7, 1999
Significance of Inducible VT in Unexplained Syncope December 1999:2023–30
length of #220 ms and no identifiable isoelectric interval
between QRS complexes.
Follow-up. July 31, 1996 was prospectively determined as
the last day of data collection for the principal analysis. A
repeat analysis was performed in December 1998; by this
time, one patient in the syncope group and four in the
control group were unavailable for follow-up. Stored ECGs
and RR intervals from ICDs were interpreted by one
investigator (E.N.P.) who was blinded to the grouping of
the patient. Published guidelines on the interpretation of
stored data were adopted (22–24). Specifically, tachyar-
rhythmias that were preceded by syncope or near syncope,
whose onset was associated with an abrupt change in
configuration, whose RR intervals varied by #30 ms once
initiated or that had a mean RR interval ,240 ms were
defined as appropriate. In indeterminate cases, data such as
the cycle length of tachyarrhythmia (CLs) of previously
documented atrial and ventricular arrhythmias, patient in-
terviews, Holter or treadmill recordings or lead integrity
testing were sought. A conservative approach was adopted:
where reasonable doubt existed, the episode was categorized
as inappropriate.
Cardiac transplantation and nonsudden deaths were re-
corded and analyzed separately but did not count as arrhyth-
mia events. Sudden death was defined as death within 1 h of
onset of cardiac symptoms. All patients in the study groups
were included in the Kaplan-Meier analysis of ICD events
and those who died, underwent transplantation or com-
pleted follow-up without receiving an appropriate ICD
therapy were left censored. Electrocardiographically docu-
mented episodes of sustained VT that occurred at rates
below the programmed cutoff for the device were counted as
events. Histories of syncope or near syncope unrelated to
ICD episodes were actively sought from patient charts and
interviews.
Statistical methods. Baseline clinical and electrophysi-
ologic characteristics were compared by Fisher exact test or
by unpaired t tests. Kaplan-Meier curves were compared by
the log rank method. The baseline characteristics listed in
Table 1, the number of extrastimuli required for induction
and the cycle lengths of the induced rhythm were all
analyzed for prediction of events among the syncope group
by Mantel Cox survival comparisons (this identified only
two characteristics with p values #0.1, thus no multivariate
analysis was performed). Data comparing VT cycle lengths
in cases and control subjects were “disconnected” and thus a
one-way analysis of variance (ANOVA) was used. Compar-
isons of CL data within each group were made by one-way
repeated measures ANOVA (control group) and paired t
test (syncope group). Correlations were tested by Pearson’s
method. P values ,0.05 were assigned significance. Two-
tailed p values were exclusively used. Mean values (6SEM)
were used unless otherwise indicated.
RESULTS
Patient characteristics. There were 22 patients in the
syncope group and 32 in the control group. Both groups had
similar ages (69 6 2 and 66 6 1 years, respectively) and men
predominated (82% and 78% respectively, Table 1). In the
syncope group 17 had syncope and 5 had near syncope.
Those with near syncope were all sufficiently concerned
Table 1. Clinical Characteristics*
Syncope
(n 5 22)
Control
(n 5 32)
p
Value
Age, yrs 6 SEM 69 6 2 66 6 1 0.11
Male 18 (82) 25 (78) 1.00
LV ejection fraction, % 6 SEM 30 6 3 29 6 2 0.73
Nonsustained VT 11 (50) 8 (25) 0.08
Underlying heart disease
Coronary artery disease 19 (86) 28 (88) 1.00
Myocardial infarction 12 (55) 24 (75) 0.15
Segmental LV dysfunction 17 (77) 26 (81) 0.74
LV aneurysm 2 (9) 8 (25) 0.17
3-vessel disease 8 (36) 14 (44) 0.78
CABG 7 (32) 15 (47) 0.40
Dilated cardiomyopathy 2 (9) 2 (6) 1.00
Other 1 (5) 2 (6) 1.00
Congestive heart failure 14 (64) 11 (34) 0.052
NYHA class III/IV 6 (27) 4 (13) 0.29
Hypertension 11 (50) 11 (34) 0.28
Diabetes mellitus 7 (32) 4 (13) 0.10
Bundle branch block 10 (45) 8 (25) 0.15
*Values are number of subjects (%) with characteristic unless otherwise stated.
LV 5 left ventricle; CABG 5 coronary artery bypass grafting; NYHA 5 New York Heart Association functional
classification.
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about their symptoms to seek medical attention within 48 h
of the episode. Twenty-two of the control subjects (69%)
had syncope or near syncope at the time of their spontane-
ous documented sustained VT. The vast majority of both
groups had underlying coronary artery disease (Table 1).
The exceptions were two cases of idiopathic dilated cardio-
myopathy in each group, one case of hypertensive cardio-
myopathy in the syncope group, one case of valvular heart
disease and one with hemodynamically unstable and drug-
resistant idiopathic VT in the control group. Although the
extent of coronary disease and left ventricular ejection
fraction was similar in both groups, a history of congestive
cardiac failure was more common in the syncope group
(Table 1).
Prior to ICD implantation, EPS guided serial drug
testing was more commonly performed in control subjects
than cases (Table 2). The median number of failures to
respond to drug therapy was 1 (range 1 to 3) for both
groups. ICDs with stored electrograms (as opposed to
stored RR intervals) were more frequent in the control
group, whereas transvenous systems were more common
among the syncope group (Table 2).
Electrophysiology testing. The syncope and control
groups had identical His to ventricular conduction time
(HV) intervals and minimum CLs that maintained 1:1 AV
conduction (Table 2). The corrected sinus node recovery
times for the syncope group were normal in all but one
patient (866 ms) who subsequently had sustained VT during
follow-up (CL, 219 ms) associated with syncope. There
were no significant differences in the number or coupling
intervals of extrastimuli required for arrhythmia induction
between the groups (Table 2).
The CLs of induced monomorphic tachycardias were
significantly shorter in the syncope group than in control
subjects (Table 2). In both groups, the VT induced at EPS
was shorter (11 6 2%) than spontaneous episodes (Figs. 1A
and 1B). Despite these differences in average VT CLs, the
CLs of induced monomorphic tachycardias correlated pos-
itively with those of subsequent spontaneous monomorphic
tachycardias (R 5 0.6, p , 0.0001 for both groups com-
bined). This correlation was particularly evident in the
syncope group (Fig. 2).
Follow-up. Complete follow-up data were available for the
first 18 months after ICD implantation and 90% of patients
Table 2. Electrophysiologic and ICD Characteristics
Syncope
(n 5 22)
Control
(n 5 32)
p-
Value
Sinus and AV node function
Sinus CL 817 6 30 819 6 27 0.96
cSNRT 363 6 59
AH 73 6 4 81 6 4 0.19
HV 59 6 4 59 6 3 0.90
AVN 1:1 385 6 16 401 6 13 0.45
PVS induction characteristics
paced CL (S1–S1) 477 6 17 469 6 15 0.71
S1–S2 coupling interval 264 6 3 279 6 12 0.28
S2–S3 coupling interval 216 6 5 228 6 5 0.09
S3–S4 coupling interval 205 6 6 212 6 5 0.41
induction with S2, n (%) 0 (0) 1 (3) 1.00
induction with S3, n (%) 12 (55) 12 (38) 0.27
induction with S4, n (%) 10 (45) 19 (59) 0.41
Serial EP guided drug testing* 3 (14) 13 (41) 0.039
ICD
Tranvenous system 22 (100) 23 (72) 0.007
Noncommitted shocks 22 (100) 32 (100) 1.00
Stored electrograms† 11 (50) 26 (81) 0.020
Arrhythmias (CL)‡
Presenting MVT-S N/A 315 6 10
Induced monomorphic arrhythmia 256 6 7 282 6 7 0.047§
MVT-S, n (%) 19 (86) 30 (94) 0.39
ICD arrhythmia 287 6 18 298 6 10 0.47§
Values are in milliseconds (mean 6 SEM) unless otherwise stated. cSNRT 5 corrected sinus node recovery time; AVN 1:1 5
minimum paced cycle length that maintained 1:1 AV conduction; PVS 5 programmed ventricular stimulation; S1–S2 5 first
extrastimulus following train of 8 paced beats; S2–S3 5 second extrastimulus; S3–S4 5 third extrastimulus; MVT-S 5
monomorphic sustained ventricular tachycardia.
*All patients who underwent electrophysiology guided drug therapy failed to respond to at least one drug.
†Devices without stored electrograms had stored RR intervals.
‡Includes only monomorphic tachycardias. Proportions were compared by Fisher exact test and numerical data by t tests,
except where indicated (§one-way ANOVA).
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were followed up for 34 months. Median length of
follow-up (including nonsurvivors) was 34 (range, 2 to 60)
and 46 (7 to 82) months in syncope and control groups,
respectively. Kaplan-Meier analysis of the time to defibril-
lator therapy for syncope and control groups produced
overlapping curves (p 5 0.9) (Fig. 3). The proportion of
syncope patients and control subjects receiving an appropri-
ate defibrillator therapy (Fig. 4) by 12 months was 57 6
11% and 50 6 9%, respectively, and by 24 months, these
proportions were 63 6 11% and 63 6 9%, respectively. Of
the 14 patients in the syncope group with an ICD VT, 8
had syncope or near syncope and an additional patient
received therapy while asleep.
Two patients in the syncope group had syncope that was
not associated with an ICD event. One of these was
clinically diagnosed as having hypoglycemia and the other
was diagnosed as having neurocardiogenic syncope. The
latter patient also had syncope that immediately preceded an
appropriate ICD defibrillation. Three patients in the syn-
cope group had ventricular flutter or fibrillation induced by
two extrastimuli. Two of the patients subsequently received
appropriate ICD defibrillations. In each case, syncope pre-
ceded defibrillation and the CLs recorded were 195 and
219 ms, respectively. Among the syncope group, the only
baseline clinical or electrophysiology characteristics that
were at all useful in predicting subsequent occurrence of an
appropriate ICD therapy were NYHA class III or IV and
presence of bifascicular block. Both were only marginally
Figure 1. A, Comparison of CLs of monomorphic tachycardias
induced at EPS and recorded by the ICD during follow-up for the
syncope group (squares). B, Comparison of CLs of monomorphic
tachycardias recorded at clinical presentation, induced at EPS and
recorded by ICD during follow-up for control patients (circles).
Monomorphic tachycardia includes sustained ventricular flutter
and sustained monomorphic VT. Solid bars represent means 6
SEM.
Figure 2. Plots of relation between cycle length of monomorphic
tachycardias induced at EPS and subsequent spontaneous episodes
recorded by the ICD in syncope group (A, squares) and control
group (B, circles). Monomorphic tachycardia includes sustained
ventricular flutter and sustained monomorphic VT.
Figure 3. Kaplan-Meier “survival” estimates for time to first
appropriate ICD event in cases with unexplained syncope and
control subjects with documented sustained VT. The number of
patients remaining in the study at six monthly intervals are
indicated below the abscissa.
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significant for a subgroup analysis (p 5 0.04 and p 5 0.03,
respectively).
Syncope and control survival curves remained overlapping
when cases with only a history of near syncope were
excluded (p 5 0.9 for difference between curves), when
patients with ventricular flutter or fibrillation induced at
EPS were excluded (p 5 0.8) or when those who had
previously failed serial drug testing had been excluded (p 5
0.8). Indeed, among the control subjects (syncope group
data could not be analyzed as only three patients underwent
serial drug testing), failure of antiarrhythmic drug therapy to
suppress induced VT did not predict subsequent occurrence
of an appropriate ICD therapy (p 5 0.4).
During follow-up, three cardiac transplantations and
seven deaths (five cardiac, no sudden deaths) occurred in the
syncope group compared with two transplants and five deaths
(all cardiac, one sudden) among the control subjects (36-
month survival without transplant, 52 6 11% and 83 6 7%,
respectively, p 5 0.03). Excluding transplantations, the 36-
month actuarial survival rate was 60 6 12% in the syncope
group and 89 6 6% in the control group (p 5 0.06).
DISCUSSION
This study provides three lines of evidence to support the
diagnostic value of induced sustained VT at EPS in patients
Figure 4. Surface ECGs and intracardiac electrogram (RV, right ventricular outflow tract) recorded at induction of monomorphic VT
(CL, 225 ms) during baseline EPS in a patient with unexplained syncope (A). Stored ICD intracardiac electrogram recorded between
proximal and distal shocking electrodes (B) in the same patient two and a half months later. This spontaneous tachycardia (rate 265
beats/min, CL 226 ms) resulted in syncope and was terminated by a 34-J shock.
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with unexplained syncope: 1) the incidence of VT during
follow-up in the syncope patients was identical to control
patients with previously documented spontaneous VT; 2)
nearly 40% of syncope patients had spontaneous recurrence
of syncope as a result of VT that was recorded and
terminated by the ICD; and 3) the rate of the induced VT
positively correlated with that subsequently recorded by the
ICD.
Although this study was not designed to compare mor-
tality between the two groups, it is noteworthy that the
actuarial incidence of nonsudden death and cardiac trans-
plantation at three years was significantly higher in the
syncope (48%) than control group (17%). This occurred
despite effective ICD therapy that prevented all but one
sudden death. The poorer prognosis in the syncope group
was consistent with a significantly higher incidence of
congestive heart failure at baseline.
The absence of antiarrhythmic drug therapy in all study
patients at the time of their baseline spontaneous event,
EPS and follow-up provided a unique opportunity to
examine the relationship between VT induced at EPS and
subsequent spontaneous episodes recorded by the ICD.
This showed that the induced VT rates were on average
significantly faster than spontaneous episodes, but the rates
were positively correlated. Although a correlation of QRS
configuration cannot be performed between the induced and
subsequent spontaneous VT (ICD), the comparative VT
rates suggests that the VT at EPS was not merely a marker
for a group prone to sustained VT, but actually identified
the cause of the syncope. Actuarial analysis of the incidence
of appropriate ICD therapies in this study suggests that
approximately 70% of patients with unexplained syncope
and inducible VT will eventually have spontaneous sus-
tained VT.
Comparison with previous studies. Previous studies using
similar pacing protocols to this present study have reported
induction of sustained ventricular arrhythmias in 21% to
50% of patients with unexplained syncope and structural
heart disease (11,12,25,26). Patients with negative results
from electrophysiologic testing have a very low incidence of
sudden death (1% per year) (4,12). Patients with positive
test results have a poorer prognosis, which is due to both an
increased risk of nonsudden cardiac death and sudden death
that occurred despite antiarrhythmic therapy (17–21). The
reported high mortality rate in these studies likely reflects
the severity of underlying heart disease; indeed, a multivar-
iate analysis suggested that in this population, ejection
fraction was of primary importance in predicting survival
(20). These reports are consistent with our data in that we
found a high overall mortality even though there were no
sudden deaths in our group of patients with unexplained
syncope treated by ICD implantation.
The incidence of appropriate shocks reported in this
study was higher than previously reported for unselected
recipients of ICDs who frequently received antiarrhythmic
drugs (27). However, in patients with documented VT who
received ICD therapy without antiarrhythmic drugs, the
actuarial incidence of VT at 12 months was 50% (24), a
comparable incidence to this present study. This suggests
that our control group was a representative sample of
patients with documented VT. In a recent study of patients
with unexplained syncope, there was a 22% one-year prob-
ability of an ICD shock (28). However, a significant
proportion of patients were treated with antiarrhythmic
drug therapy that may have prevented recurrent VT. An-
other recent study reported a 66% one-year probability of an
appropriate ICD therapy in a small subgroup with unex-
plained syncope and inducible monomorphic VT (29).
Study limitations. The vast majority of patients included
in this study had coronary artery disease with left ventricular
dysfunction. Since programmed ventricular stimulation is
less sensitive and less specific in patients with nonischemic
cardiomyopathies (3), the results of this study cannot
necessarily be extrapolated to such patients. Similarly, our
study used a maximum of three extrastimuli and excluded
patients with ventricular flutter or fibrillation induced by
more than two extrastimuli. Results from this study should
not be applied to the use of more aggressive pacing
protocols.
Despite restricting the study to patients with ICDs that
had stored electrograms or RR intervals, we cannot assume
that all apparently appropriate ICD events were due to
ventricular tachyarrhythmias. As the interpreting electro-
physiologist was blinded to group allocation, any such errors
should have affected cases as much as control subjects.
Including only ICDs with event storage capabilities and
excluding patients receiving antiarrhythmic drugs improved
the ability of the study to estimate the true incidence of
spontaneous tachyarrhythmias, but resulted in a relatively
small sample size. Finally, the successful cardioversion of
suspected VT should not be equated with prevention of
sudden death.
Clinical implications. In patients with coronary artery
disease, impaired left ventricular function and unexplained
syncope, induction of sustained VT at EPS reliably identi-
fies those at risk of potentially life-threatening ventricular
tachyarrhythmias. In these patients, aggressive treatment
directed toward the prevention of such arrhythmias is
warranted. Since they may also have an increased risk of
nonarrhythmic death, clinical management should include
aggressive treatment of their underlying cardiac disease.
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